VEGF-blocking antibodies or tyrosine kinase inhibitors are routinely used ... a strategy to interfere simultaneously with both VEGFR-2 and VEGFR-3 function, which could be used as an alternative ...
Similar data were observed with sunitinib, a Vegfr and platelet-derived growth factor receptor (Pdgfr) kinase inhibitor currently in clinical use, when administered continuously for 5 weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback